Waste Management, Inc. (WM) — Q2 2026 Earnings Preview

Company

Waste Management, Inc. (NYSE: WM)

Upcoming Earnings

Q2 2026 — July 28, 2026 (After Market Close); Conference Call July 29, 2026 at 10:00 AM ET

Reporting Period

Q2 2026 (April 1 – June 30, 2026)

Prepared

July 28, 2026

Sector ETF Benchmark

Peers: RSG, WCN (waste sector comparables)

1. Earnings Preview

Key Takeaway: The setup is modestly constructive — consensus is an achievable bar with Q2 Operating EBITDA at ~$2.03B and Adj. EPS at ~$1.98, and the single biggest swing factor is whether wildfire volume comps (~$85M revenue headwind vs. Q2 2025) are offset by Healthcare Solutions inflection and RNG ramp.

Heading into Q2 2026, WM faces its toughest year-over-year comparison of the year — management explicitly flagged the ~$85M wildfire revenue headwind from Q2 2025 — yet the underlying business is tracking well, with special waste ex-wildfire running strongly, industrial volumes returning to modest positive growth after six-to-seven consecutive negative quarters, and Healthcare Solutions on track for an H2 revenue inflection. Consensus estimates have barely moved since the Q1 print (Operating EBITDA up just ~$2M, EPS up ~$0.003 vs. the post-Q1 baseline), suggesting the Street has already absorbed the wildfire comp and is not pricing in meaningful upside. Three additional RNG facilities were expected online in Q2, and the IRS production tax credit confirmation (~$30–35M annually through 2029) provides a structural EPS tailwind that may not be fully reflected in consensus. The stock has gained ~4.6% since the Q1 print (vs. RSG +4.2%, WCN +3.6%), suggesting the market has partially priced in execution continuity but not a material beat. The wildcard is Healthcare Solutions: if customer credits continue declining faster than expected and revenue growth inflects toward the guided mid-single-digit H2 exit rate, that could be the positive surprise that drives the stock — conversely, any sign of renewed billing disruption or customer churn would be the key downside risk.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar — Operating EBITDA of $2.03B implies ~5.7% YoY growth against a tough wildfire comp, and core price at ~6.1% remains the more reliable beat lever; volume growth (consensus: -0.14%) is the bigger swing factor given macro uncertainty flagged by peer WCN.

Table 1 — Q2 2026 Current Quarter Snapshot

KPI

Q1 2026 Actual

Q2 2025 Actual (Prior Year)

Q2 2026 Consensus Est.

YoY Change

Guidance

Consensus vs. Guidance

Revenue ($B)

$6.227B

$6.430B

$6.707B

+4.3%

FY 2026: $26.5B (implied ~$6.6–6.7B/Q avg)

~In line

Operating EBITDA ($B)

$1.853B

$1.923B

$2.032B

+5.7%

FY 2026: $8.15–8.25B

~In line (midpoint $8.20B)

Operating EBITDA Margin (%)

29.8%

29.9%

30.3%

+40 bps

FY 2026: ~30.9%

~In line

Adj. EPS (Diluted)

$1.81

$1.92

$1.98

+3.1%

FY 2026: ~$8.17

~In line

Core Price (C&D) (%)

6.3%

6.4%

~6.1%

-30 bps

FY 2026: ~5.9%

~In line

Volume Growth (%)

+0.2% (reported); -1.5% C&D ex-weather

+2.1%

-0.14%

-230 bps

Wildfire comp headwind; improvement expected H2

N/A (no explicit Q2 vol guidance)

Free Cash Flow ($B, Co. Defined)

$0.920B

$0.818B

$1.072B

+31.1%

FY 2026: ~$3.87B

~In line

Capital Expenditures ($B)

$0.650B

$0.732B

$0.665B

-9.2%

FY 2026: ~$2.71B (step-down from sustainability CapEx)

~In line

Sources: Visible Alpha Consensus and Actuals Data

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Operating EBITDA & Adj. EPS)

Quarter

KPI

Reported

Consensus

Surprise %

Result

Q1 2026

Operating EBITDA

$1.853B

$1.872B

-1.0%

Miss

Q1 2026

Adj. EPS

$1.81

$1.75 (consensus at time of print)

+3.4%

Beat

Q4 2025

Operating EBITDA

$1.974B

$1.934B

+2.1%

Beat

Q4 2025

Adj. EPS

$1.93

$1.94

-0.5%

Miss

Q3 2025

Operating EBITDA

$1.970B

$1.970B

0.0%

In Line

Q3 2025

Adj. EPS

$1.98

$2.03

-2.5%

Miss

Q2 2025

Operating EBITDA

$1.923B

$1.880B

+2.3%

Beat

Q2 2025

Adj. EPS

$1.92

$1.89

+1.6%

Beat

Q1 2025

Operating EBITDA

$1.750B

$1.718B

+1.9%

Beat

Q1 2025

Adj. EPS

$1.67

$1.60

+4.4%

Beat

Q4 2024

Operating EBITDA

$1.706B

$1.703B

+0.2%

Beat

Q4 2024

Adj. EPS

$1.70

$1.79

-5.0%

Miss

Q3 2024

Operating EBITDA

$1.711B

$1.686B

+1.5%

Beat

Q3 2024

Adj. EPS

$1.96

$1.91

+2.6%

Beat

Q2 2024

Operating EBITDA

$1.618B

$1.637B

-1.2%

Miss

Q2 2024

Adj. EPS

$1.82

$1.84

-1.1%

Miss

Pattern: WM has beaten Operating EBITDA consensus in 5 of the last 8 quarters, with beats concentrated in periods of strong special waste and wildfire-related volumes; EPS beats have been more consistent (5 of 8) driven by tax benefits and buybacks, though Q4 2024 and Q3 2025 saw notable EPS misses tied to integration costs and volume softness. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been unchanged since the Q1 2026 earnings call (April 28, 2026) — no post-earnings 8-K or conference update has revised numbers — but tone has been constructive, with management flagging Q2 as the toughest comp of the year and expressing confidence in H2 margin lift and Healthcare Solutions revenue inflection.

Metric

Initial Guidance (Q1 2026 Earnings Call, Apr 28)

Revised Guidance

Current Consensus

Note

FY 2026 Revenue

~$26.5B (implied from EBITDA margin guidance)

$26.54B

Unchanged; management confirmed full-year revenue guidance achievable

FY 2026 Operating EBITDA

$8.15B–$8.25B

$8.20B

Unchanged; consensus at midpoint; management “very comfortable with the whole range”

FY 2026 Free Cash Flow

~$3.87B (company-defined)

$3.87B

Unchanged; Q1 FCF of $920M nearly doubled YoY, tracking well; FCF conversion ~46%

FY 2026 Adj. EPS

~$8.17 (implied)

$8.17

Unchanged; effective tax rate now guided ~23% for FY (vs. 18% in Q1 due to RNG PTCs)

Sustainability EBITDA Contribution

$240M–$250M benefit to EBITDA

~$245M (midpoint)

Unchanged; 3 more RNG facilities expected online in Q2, rest in H2; interconnect delays noted but long-term targets intact

Healthcare Solutions Revenue Growth

~3% FY 2026; mid-single-digit H2 exit rate

~3% FY 2026

Unchanged; management “super optimistic”; customer credits peaked Q4 2025, declining in Q1/Q2, expected to “really reverse” in Q3/Q4

Share Repurchases

$2.0B for FY 2026; 55–60% weighted to H2

On track

Unchanged; $344M repurchased in Q1; leverage returned to target range of 2.5–3.0x (2.94x at Q1 end)

Capital Expenditures

~$2.71B FY 2026 (sustainability CapEx program substantially complete in 2026)

$2.71B

Unchanged; CapEx ~22% lower YoY in Q1; sustainability build-out entering “harvest” phase

Q2 2026 Tone / Qualitative

Q2 is “tough comp”; ~$85M wildfire revenue headwind; margin improvement “muted” by wildfire absence; H2 margin to “lift nicely”

N/A

Management committed to guidance refresh after Q2; volume guidance update expected on this call

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the Q1 print — Q2 Operating EBITDA consensus moved up just ~$2M and FY 2026 EBITDA up ~$6M — suggesting the Street has fully absorbed the wildfire comp headwind and is not pricing in incremental upside from RNG ramp or Healthcare Solutions inflection; the gap between consensus and guidance midpoint is minimal, leaving little cushion if volumes disappoint.

KPI (Period)

Estimate ~5 Days Post Q1 Print (May 5, 2026)

Current Consensus (Jul 28, 2026)

Estimate Δ (%)

Initial Guidance (Q1 Call)

Current Guidance

Guidance Δ

Consensus vs. Guidance (%)

Revenue — Q2 2026

$6.685B

$6.707B

+0.3%

FY implied ~$6.6–6.7B/Q

Unchanged

~In line

Revenue — FY 2026

$26.508B

$26.544B

+0.1%

~$26.5B (implied)

Unchanged

~In line

Operating EBITDA — Q2 2026

$2.030B

$2.032B

+0.1%

FY $8.15–8.25B (Q2 implied ~$2.0B+)

Unchanged

~In line (midpoint)

Operating EBITDA — FY 2026

$8.196B

$8.202B

+0.1%

$8.15B–$8.25B

Unchanged

~At midpoint

Adj. EPS — Q2 2026

$1.979B

$1.982

+0.2%

FY ~$8.17

Unchanged

~In line

Adj. EPS — FY 2026

$8.163

$8.173

+0.1%

~$8.17 (implied)

Unchanged

~In line

Free Cash Flow — Q2 2026

$1.018B

$1.072B

+5.3%

FY ~$3.87B

Unchanged

~In line

Free Cash Flow — FY 2026

$3.820B

$3.868B

+1.3%

~$3.87B

Unchanged

~In line

Estimates have been essentially flat since the Q1 print, with all key metrics moving less than 0.3% — the Street has fully digested the wildfire comp headwind and is not pricing in incremental upside from RNG ramp, Healthcare Solutions inflection, or the IRS production tax credit benefit (~$30–35M annually through 2029). Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: WM has gained ~4.6% since the Q1 2026 earnings date (April 28), modestly outperforming RSG (+4.2%) and WCN (+3.6%), with the move driven primarily by multiple re-rating and FCF inflection confidence rather than estimate revisions (which were flat); the stock is not pricing in a material beat, leaving room for upside if Healthcare Solutions or RNG surprise positively.

WM vs. RSG vs. WCN — Indexed Price Performance Since Q1 2026 Earnings (April 28, 2026 = 100). Source: Stock Price Data.

WM closed at $227.35 on April 28 (Q1 earnings day) and at $237.90 on July 28, 2026, a gain of +$10.55 / +4.64%. RSG gained +4.2% and WCN gained +3.6% over the same period. The sector moved broadly in line, suggesting WM’s performance reflects sector-level re-rating rather than company-specific alpha. Key events during the period: (1) May 13 — COO appointment (Tara Hemmer) and Healthcare Solutions leadership transition (Carrasco retirement); (2) May 14 — shareholder vote approving executive pay and expanded stock plan; (3) July 7 — notable sector-wide rally (+3.5% for WM on the day) likely driven by macro/rate sentiment; (4) July 16 — WM hit an intra-period high of $242.25 before pulling back modestly into the print. Source: Stock Price Data.

6. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: WCN’s Q2 2026 print (July 22) is the most direct read-through — solid pricing (+6.7% total price) but volume weakness (-1.9%) driven by macro uncertainty and fuel-related churn is a cautionary signal for WM’s volume line; however, WCN’s July commentary (special waste, C&D, MSW all improving) and CWST’s “normal seasonal uptick” tone suggest Q2 was the trough and H2 should be better.

WCN — Q2 2026 Earnings (Reported July 22–23, 2026)

Relevance to WM: WCN is WM’s closest direct peer in solid waste collection, transfer, and disposal. Its Q2 2026 results are the most timely and direct read-through for WM’s current reporting quarter.

CWST (Casella Waste Systems) — Stifel Investor Summit (June 10, 2026) & William Blair Conference (June 2, 2026)

Relevance to WM: CWST operates primarily in the Northeast/Mid-Atlantic, overlapping with WM’s key markets. Commentary on landfill capacity, pricing dynamics, and volume trends is directly relevant to WM’s collection and disposal business.

CLH (Clean Harbors) — Wells Fargo Industrials Conference (June 9) & Stifel Investor Summit (June 10, 2026)

Relevance to WM: CLH operates in hazardous/industrial waste — less direct overlap with WM’s solid waste business, but relevant for industrial activity trends, macro read-through, and the broader waste industry environment.

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the COO appointment of Tara Hemmer (May 13) — a 27-year WM veteran who led the sustainability build-out — which signals operational continuity and accelerated technology transformation; the simultaneous retirement of Healthcare Solutions President Rafael Carrasco (effective July 17) is the key watch item for integration execution risk.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by executives since the Q1 print — all transactions are either equity award grants (code A) or routine tax-withholding shares (code F); the only open-market sale was by departing Healthcare Solutions President Carrasco (June 5), which is retirement-driven and not a signal on business outlook.

Name

Title

Transaction Type

Shares

Date

Note

Rafael Carrasco

SVP Enterprise Strategy / President, WM Healthcare Solutions

Open Market Sale (Code S)

2,655 shares

Jun 5, 2026

Retirement-driven; Carrasco announced retirement effective July 17, 2026. Sale follows option exercise (Code M). Not a discretionary bearish signal.

Tara Hemmer

EVP & Chief Operating Officer

Equity Award Grant (Code A)

2,544 shares

May 20, 2026

RSU grant in connection with COO promotion (grant date May 20, 2026; value $575,000). Vests 34%/33%/33% over 3 years. Not a market transaction.

Marcel Dalby

SVP Business Optimization & Collection

Equity Award Grant (Code A)

2,257 shares

May 20, 2026

Annual equity award grant. Not a market transaction.

John Morris

President

Tax Withholding (Code F)

566 shares

May 20, 2026

Shares withheld for tax obligation on vesting RSUs. Routine; not a discretionary sale.

Thomas Bene

Director

Equity Award Grant (Code A)

861 shares

May 15, 2026

Annual director equity grant. Not a market transaction.

Bruce Chinn

Director

Equity Award Grant (Code A)

861 shares

May 15, 2026

Annual director equity grant. Not a market transaction.

Andres Gluski

Director

Equity Award Grant (Code A)

861 shares

May 15, 2026

Annual director equity grant. Not a market transaction.

Victoria Holt

Director

Equity Award Grant (Code A)

861 shares

May 15, 2026

Annual director equity grant. Not a market transaction.

Kathleen Mazzarella

Director

Equity Award Grant (Code A)

1,314 shares

May 15, 2026

Annual director equity grant (higher share count reflects committee chair premium). Not a market transaction.

Sean Menke

Director

Equity Award Grant (Code A)

861 shares

May 15, 2026

Annual director equity grant. Not a market transaction.

William Plummer

Director

Equity Award Grant (Code A)

861 shares

May 15, 2026

Annual director equity grant. Not a market transaction.

Maryrose Sylvester

Director

Equity Award Grant (Code A)

861 shares

May 15, 2026

Annual director equity grant. Not a market transaction.

Summary: No open-market buys or discretionary sells by any executive or director since the Q1 2026 print. All transactions are routine equity award grants (annual director grants, COO promotion RSUs) or tax-withholding events. The only open-market sale (Carrasco, June 5) is clearly retirement-driven following his announced departure. Insider activity is neutral — no signal either way on the Q2 print. Source: Insider Transaction Data (Form 4 filings).